Trial Profile

A Randomized, Double-blind, Placebo-controlled, Multicenter, Adaptive Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in the Treatment of Ulcerative Pyoderma Gangrenosum

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 08 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vilobelimab (Primary) ; Betamethasone; Cortisone; Dexamethasone; Fludrocortisone; Hydrocortisone; Methylprednisolone; Prednisolone; Prednisone; Triamcinolone
Indications Pyoderma gangrenosum
Focus Registrational; Therapeutic Use
Sponsors InflaRx

30 Dec 2025 According to an InflaRx media release, Primary endpoint has not been met. (Efficacy of treatment with vilobelimab compared to placebo)
30 Dec 2025 According to an InflaRx media release, company anticipates meeting with the FDA to discuss a potential path forward for vilobelimab in PG, including the use of alternative endpoints that could be utilized for potential future clinical studies.
30 Dec 2025 Results presented in the InflaRx Media Release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com